Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
SGLT2 Inhibitors for Type 2 Diabetes with CKD Stage 3b-4
Recruiting1 awardPhase 1
Dallas, Texas
This trial is designed to see if Effervescent calcium magnesium citrate (EffCaMgCitrate) and dapagliflozin have an effect on surrogate markers of kidney and cardiovascular health in patients with stage 3b-4 Chronic Kidney Disease (CKD). 30 patients will be recruited and randomly assigned to one of three groups: placebo, CaMgcitrate 480mg Mg, or dapagliflozin 10mg. The trial will last 24 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.